PMV Pharmaceuticals (PMVP) Change in Accured Expenses (2019 - 2026)

PMV Pharmaceuticals (PMVP) has 8 years of Change in Accured Expenses data on file, last reported at -$1.2 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 27.55% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $869000.0 (up 119.24% YoY) and the FY2025 annual result came in at $418000.0, up 116.71% from the prior year.
• Change in Accured Expenses slipped to -$1.2 million in Q1 2026, from -$658000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $4.6 million in Q3 2024 to a low of -$4.6 million in Q2 2024.
• A 5-year average of -$115058.8 and a median of -$117000.0 in 2025 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 314.94% in 2024, down 676.13% in 2024.
• Tracing PMVP's Change in Accured Expenses over 5 years: stood at $872000.0 in 2022, then rose by 3.44% to $902000.0 in 2023, then slumped by 412.42% to -$2.8 million in 2024, then soared by 76.65% to -$658000.0 in 2025, then slumped by 80.24% to -$1.2 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.2 million (Q1 2026), -$658000.0 (Q4 2025), and -$117000.0 (Q3 2025), per Business Quant data.